PSP Research LLC
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, the newest measured quarter, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 94.6%; sector active share 78.0% against the combined 13F book's sector weights.
Over time 3 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
44 tracked positions · as of Sep 30, 2026 · Δ vs Jun 30, 2026Portfolio Trend
Sector Breakdown
As of Sep 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Unclassified | 90.1% | $131,419,320 |
| Healthcare | 9.9% | $14,412,088 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedTrimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| XBI | State Street(R) SPDR(R) S&P(R) Biotech ETF | −183,500 | 386,500 | $60,943,320 | |
| ARDX | Ardelyx, Inc. | −30,000 | 30,000 | $102,600 | |
| TRVI | Trevi Therapeutics, Inc. | −15,000 | 15,000 | $214,800 | |
| AUPH | Aurinia Pharmaceuticals Inc. | −15,000 | 15,000 | $242,925 | |
| NRIX | Nurix Therapeutics, Inc. | −13,000 | 12,000 | $284,520 | |
| DYN | Dyne Therapeutics, Inc. | −10,000 | 10,000 | $161,100 | |
| ARQT | Arcutis Biotherapeutics, Inc. | −9,700 | 10,000 | $264,300 | |
| IMCR | Immunocore Holdings plc | −8,141 | 7,000 | $212,030 | |
| SNDX | Syndax Pharmaceuticals Inc | −8,000 | 12,000 | $225,600 | |
| CMPS | COMPASS Pathways plc | −8,000 | 10,000 | $124,400 | |
| IMNM | Immunome Inc. | −6,000 | 12,000 | $258,120 | |
| RPRX | Royalty Pharma plc | −6,000 | 5,000 | $291,800 | |
| IMVT | Immunovant, Inc. | −6,000 | 7,000 | $236,460 | |
| TGTX | Tg Therapeutics, Inc. | −5,000 | 5,000 | $278,900 | |
| HALO | Halozyme Therapeutics, Inc. | −4,000 | 3,000 | $331,200 | |
| DFTX | Definium Therapeutics, Inc. | −3,500 | 6,500 | $247,390 | |
| TARS | Tarsus Pharmaceuticals, Inc. | −3,500 | 3,500 | $275,135 | |
| INCY | Incyte Corp | −3,300 | 2,000 | $242,700 | |
| HRMY | Harmony Biosciences Holdings, Inc. | −3,000 | 7,000 | $274,820 | |
| STOK | Stoke Therapeutics, Inc. | −3,000 | 9,000 | $234,000 | |
| EXEL | Exelixis, Inc. | −3,000 | 5,000 | $292,050 | |
| KYMR | Kymera Therapeutics, Inc. | −2,000 | 2,000 | $223,580 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | −1,500 | 3,500 | $261,135 | |
| PTGX | Protagonist Therapeutics, Inc | −1,500 | 1,500 | $211,335 | |
| NBIX | Neurocrine Biosciences Inc | −1,200 | 1,800 | $255,312 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SERA | Sera Prognostics, Inc. | 2,396,685 | $5,009,071 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | 8,000 | $585,120 | |
| RAPP | Rapport Therapeutics, Inc. | 14,000 | $583,380 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 17,000 | $567,630 | |
| GLUE | Monte Rosa Therapeutics, Inc. | 23,000 | $556,600 | |
| IONS | Ionis Pharmaceuticals Inc | 6,800 | $539,172 | |
| PHVS | Pharvaris N.V. | 15,000 | $518,700 | |
| ACAD | Acadia Pharmaceuticals Inc | 19,766 | $500,079 | |
| PTCT | Ptc Therapeutics, Inc. | 6,000 | $489,420 | |
| CLDX | Celldex Therapeutics, Inc. | 13,000 | $483,730 | |
| COGT | Cogent Biosciences, Inc. | 12,000 | $464,400 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 1,465 | $441,008 | |
| — | 11,000 | $411,620 | ||
| NAMS | NewAmsterdam Pharma Co N.V. | 12,000 | $406,680 | |
| LQDA | Liquidia Corp | 5,000 | $398,650 | |
| VKTX | Viking Therapeutics, Inc. | 10,000 | $390,100 | |
| ELVN | Enliven Therapeutics, Inc. | 7,000 | $355,250 | |
| SYRE | Spyre Therapeutics, Inc. | 4,000 | $355,120 | |
| VERA | Vera Therapeutics, Inc. | 7,000 | $300,370 | |
| CRSP | CRISPR Therapeutics AG | 5,000 | $272,700 | |
| ZYME | Zymeworks Inc. | 10,000 | $261,400 | |
| XENE | Xenon Pharmaceuticals Inc. | 4,200 | $253,512 | |
| AXSM | Axsome Therapeutics, Inc. | 1,000 | $244,770 | |
| AVBP | ArriVent BioPharma, Inc. | 7,041 | $244,604 | |
| JAZZ | Jazz Pharmaceuticals plc | 971 | $233,981 | |
| KOD | Kodiak Sciences Inc. | 6,000 | $233,760 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| SGOV |
iShares 0-3 Month Treasury Bond ETF
|
Held | 700,000 | $70,476,000 | 48.33% | |
| XBI |
State Street(R) SPDR(R) S&P(R) Biotech ETF
|
Reduced | 386,500 | $60,943,320 | 41.79% | |
| SERA |
Sera Prognostics, Inc.
Healthcare
|
NEW | 2,396,685 | $5,009,071 | 3.43% | |
| HALO |
Halozyme Therapeutics, Inc.
Healthcare
|
Reduced | 3,000 | $331,200 | 0.23% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Held | 600 | $302,376 | 0.21% | |
| EXEL |
Exelixis, Inc.
Healthcare
|
Reduced | 5,000 | $292,050 | 0.20% | |
| RPRX |
Royalty Pharma plc
Healthcare
|
Reduced | 5,000 | $291,800 | 0.20% | |
| ARGX |
Argenx SE
Healthcare
|
Reduced | 300 | $287,673 | 0.20% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Reduced | 12,000 | $284,520 | 0.20% | |
| TGTX |
Tg Therapeutics, Inc.
Healthcare
|
Reduced | 5,000 | $278,900 | 0.19% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
Reduced | 3,500 | $275,135 | 0.19% | |
| HRMY |
Harmony Biosciences Holdings, Inc.
Healthcare
|
Reduced | 7,000 | $274,820 | 0.19% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $264,300 | 0.18% | |
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Reduced | 3,500 | $261,135 | 0.18% | |
| SUPN |
Supernus Pharmaceuticals, Inc.
Healthcare
|
Held | 6,000 | $258,240 | 0.18% | |
| IMNM |
Immunome Inc.
Healthcare
|
Reduced | 12,000 | $258,120 | 0.18% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
Reduced | 1,800 | $255,312 | 0.18% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 3,000 | $249,870 | 0.17% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Held | 10,000 | $249,500 | 0.17% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
Reduced | 6,500 | $247,390 | 0.17% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Held | 1,200 | $246,312 | 0.17% | |
| ALKS |
Alkermes plc.
Healthcare
|
Held | 6,000 | $243,120 | 0.17% | |
| AUPH |
Aurinia Pharmaceuticals Inc.
Healthcare
|
Reduced | 15,000 | $242,925 | 0.17% | |
| INCY |
Incyte Corp
Healthcare
|
Reduced | 2,000 | $242,700 | 0.17% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Held | 20,000 | $241,200 | 0.17% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 7,000 | $236,460 | 0.16% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Reduced | 9,000 | $234,000 | 0.16% | |
| KRYS |
Krystal Biotech, Inc.
Healthcare
|
Held | 692 | $230,131 | 0.16% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Reduced | 1,000 | $227,830 | 0.16% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Reduced | 12,000 | $225,600 | 0.15% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 2,000 | $223,580 | 0.15% | |
| DNTH |
Dianthus Therapeutics, Inc.
Healthcare
|
Held | 2,500 | $220,125 | 0.15% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 15,000 | $214,800 | 0.15% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Held | 2,500 | $213,700 | 0.15% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Reduced | 7,000 | $212,030 | 0.15% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Reduced | 1,500 | $211,335 | 0.14% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Held | 5,000 | $203,000 | 0.14% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Held | 13,000 | $175,110 | 0.12% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $161,100 | 0.11% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Reduced | 10,000 | $124,400 | 0.09% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Held | 15,000 | $115,050 | 0.08% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Held | 39,400 | $107,168 | 0.07% | |
| ARDX |
Ardelyx, Inc.
Healthcare
|
Reduced | 30,000 | $102,600 | 0.07% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Held | 10,000 | $86,400 | 0.06% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.